Ratings biote Corp.

Equities

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-01 pm EDT			5-day change	1st Jan Change
5.65 ^USD	+2.54%		+1.07%	+14.37%

Apr. 05	B. Riley Ups Price Target on Biote to $10 From $9, Maintains Buy Rating	MT
Apr. 03	CORRECTION : --B. Riley Lowers Bitcoin Depot's Price Target to $4 From $6, Maintains Buy Rating	MT

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 50% by 2026.
The company's profit outlook over the next few years is a strong asset.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
Given the positive cash flows generated by its business, the company's valuation level is an asset.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Over the past four months, analysts' average price target has been revised upwards significantly.
Analyst opinion has improved significantly over the past four months.

The firm trades with high earnings multiples: 28.25 times its 2024 earnings per share.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
BIOTE CORP.	+14.37%	196M		-
CENGAGE LEARNING HOLDINGS II, INC.	+35.90%	828M	-	D
NIIT LIMITED	-7.77%	171M		C
DAEKYO CO., LTD.	+3.28%	146M		-
FLOWSPARKS N.V.	-.--%	52.94M	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality